Information on the Target

Nu-Med, based in Poland, operates several medical centers specializing in radiation therapy. Established in collaboration with Enterprise Investors (EI) in 2013, Nu-Med has expanded its services by launching treatment centers in Elbląg, Katowice, Tomaszów Mazowiecki, and Zamość. Over the past decade, Nu-Med has maintained a strong reputation among healthcare providers, ensuring high-quality treatment and medical care for its patients, with 2023 revenues reaching an impressive 258 million PLN.

The company's growth and stability highlight its commitment to providing oncology care and its strategic importance in the Polish healthcare landscape. Under the consistent management of EI, Nu-Med has transformed from a single radiation therapy center into a major provider of oncology services in Poland.

Industry Overview in Poland

The Polish healthcare market has been evolving rapidly, driven by the increasing prevalence of chronic diseases, including cancer, which poses a significant threat to public health. According to the World Health Organization (WHO), approximately 170,000 new cancer cases and nearly 100,000 cancer-related deaths are reported in Poland each year, making it a critical area for investment and innovation.

This rising demand for specialized healthcare services has led to an increased focus on improving access to diagnostic and treatment facilities nationwide. The Polish government has initiated various healthcare reforms, including the National Oncology Strategy, aimed at enhancing the early detection and treatment of cancer. Such initiatives are crucial in addressing the rising cancer burden and improving patient outcomes.

Moreover, the increasing adoption of advanced medical technologies and an emphasis on integrated healthcare services have positioned Poland as a promising market for health service providers. The growing trend of private investment in healthcare facilities reflects the expanding role of both domestic and international players in catering to the evolving healthcare needs of the population.

The economic environment and demographic shifts, including an aging population, contribute significantly to the growth within the oncology sector. As the need for advanced cancer care doubles, companies like Nu-Med are poised to play an essential role in fulfilling these demands while enhancing the overall quality of healthcare services available in Poland.

The Rationale Behind the Deal

This acquisition represents a strategic move for Affidea Group, emphasizing their commitment to enhancing oncology care in Poland. By integrating Nu-Med into their operations, Affidea aims to leverage its existing capabilities to provide comprehensive cancer prevention, early diagnostics, and treatment services to a broader patient base.

Enterprise Investors’ decision to sell Nu-Med signifies a successful exit strategy after a decade of growth and value creation. The transaction exemplifies strong market potential while allowing Affidea to expand its footprint in a vital sector of healthcare—oncology—ensuring that high-quality services remain accessible to patients across Poland.

Information About the Investor

Enterprise Investors (EI) is a leading private equity firm in Central and Eastern Europe, established in 1990. With a track record of creating ten funds, EI has invested or committed over 2.3 billion EUR across 156 companies, successfully exiting from 140 of them. EI's strong presence in the healthcare sector reflects its dedication to supporting high-growth companies and driving transformations that enhance market efficiency.

Affidea Group, the acquirer of Nu-Med, is a pan-European provider of imaging diagnostics and specialized healthcare services, including oncology. Founded in 1991, Affidea operates 366 centers across 15 countries, serving nearly 14 million patients with high-quality medical services annually. Backed by Groupe Bruxelles Lambert (GBL), Affidea focuses on long-term value creation and innovative healthcare solutions.

View of Dealert

This deal appears to be a strategically advantageous investment for Affidea, effectively bolstering their position in the oncology sector in Poland. By acquiring Nu-Med, Affidea not only expands its service offerings but also strengthens its commitment to exceptional cancer care amidst increasing demand for such services. The acquisition is likely to attract both new patients and enhance the quality of care provided through shared resources and expertise.

For Enterprise Investors, this exit marks a successful chapter in their investment journey with Nu-Med, illustrating their capacity to catalyze growth and create value in the healthcare domain. Their involvement has positioned Nu-Med for future success under Affidea’s esteemed banner, ensuring continuity in high-standard medical services for oncology patients.

Overall, the consolidation of resources and expertise between Affidea and Nu-Med indicates a significant opportunity for improving healthcare delivery in Poland. This investment aligns well with both parties' missions, promising enhanced patient outcomes and access to comprehensive cancer care through an integrated healthcare approach.

View Original Article